Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884042 | 0.88 | ALDH1A1 (0.49) | L3MBTL1KMT2AHSPB1HTR2AHTR2C | |
| SCHEMBL27778849 | 0.85 | HSPB1 (0.48) | L3MBTL1KMT2AHSPB1TDP1ATM | |
| SCHEMBL29749978 | 0.83 | ALDH1A1 (0.52) | KMT2AHSPB1TDP1CYP1A2CYP3A4 | |
| SCHEMBL10714683 | 0.83 | ALDH1A1 (0.52) | KMT2AHSPB1TDP1CYP1A2CYP3A4 | |
| SCHEMBL28338065 | 0.82 | CYP3A4 (0.40) | KMT2ATDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5644726 | 0.82 | ALDH1A1 (0.50) | KMT2ATDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5640740 | 0.82 | CYP1A2 (0.60) | TDP1CYP1A2CYP3A4CYP2D6NPC1 | |
| SCHEMBL430707 | 0.81 | RAB9A (0.66) | L3MBTL1KMT2ATDP1NPC1RECQL | |
| SCHEMBL3065551 | 0.81 | ALDH1A1 (0.52) | KMT2ATDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27778855 | 0.80 | NPC1 (0.51) | L3MBTL1KMT2AHSPB1TDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103819343-B | The preparation method of the fluoro-6-nitrophenols of compound 2-allyl group-4-and agricultural biological activity | QINGDAO AGRICULTURAL UNIVERSITY (CN) | 2016-03-23 | — | — | CN | disclosed |
| CN-103819343-A | Preparation method of compound 2-allyl-4-fluoro-6-nitrophenol and agricultural bio-activity thereof | UNIV QINGDAO AGRICULTURAL | 2014-05-28 | — | — | CN | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| EP-1326859-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003047583-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048159-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | L3MBTL1 2710/4885KMT2A 2442/4885HSPB1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.